Laurion Capital Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Laurion Capital Management’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-19,000	Closed	-$892K	–	1227
2019 Q4	$892K	Buy	+19,000	New	+$840K	0.01%	593
2018 Q2	–	Sell	-26,182	Closed	-$139K	–	1705
2018 Q1	$139K	Buy	+26,182	New	+$187K	﹤0.01%	1258
2017 Q1	–	Sell	-40,000	Closed	-$608K	–	1675
2016 Q4	$608K	Buy	+40,000	New	+$544K	0.01%	797

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Laurion Capital Management's RARX Position: Q1 2020 in Review

Laurion Capital Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q1 2020, closing a stake of 19,000 shares — an estimated $892K sold.

Laurion Capital Management first reported a position in RARX in Q4 2016 and held it in 3 quarters. The position peaked at $892K in Q4 2019. 144 funds tracked by Wall St. Rank hold RARX as of Q1 2020.

Laurion Capital Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Laurion Capital Management sold 19,000 Ra Pharmaceuticals, Inc. Common Stock shares in Q1 2020, an estimated $892K.
Laurion Capital Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 3 quarters.
Laurion Capital Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $892K in Q4 2019.
144 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q1 2020.

Based on Laurion Capital Management's 13F filing for Q1 2020, filed 14 May 2020.